Date | Price Target | Rating | Analyst |
---|---|---|---|
5/16/2024 | $20.00 | Hold → Buy | Needham |
11/16/2023 | Hold | Needham | |
12/21/2022 | $9.00 | Underweight | Barclays |
6/17/2022 | $20.00 | Neutral | JP Morgan |
3/18/2022 | Neutral | Guggenheim |
Third Party Net Sales from Continuing Operations of $116.8 millionNet Loss from Continuing Operations of $(9.6) million; Net Loss margin of (8.2%) Adjusted EBITDA[1] from Continuing Operations of $16.1 million; Adjusted EBITDA[1] margin of 13.8%Reduced debt to $235.1 million, ended quarter with cash balance from Continuing Operations of $78.6 million PALM BEACH GARDENS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call today, August 1, 2024, at 4:30 p.m. Eastern Time. "We continued to execute in the
PALM BEACH GARDENS, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the release of its RealGUIDE® 5.4 software. The update is now available in all markets where RealGUIDE is sold, enhancing ZimVie's current RealGUIDE software suite for treatment planning and implant restoration. RealGUIDE 5.4 now helps users manage procedural risk more effectively and plan complex cases in a fraction of the time. The most significant enhancement in this version is one-click nerve detection and automated bone and tooth segmentation. This empowers clinicians with greater case insights and treatment planning confidence
PALM BEACH GARDENS, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie's portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date. The introduction of GenTek to the U.S. market brings a broad offering of differentiated restorative components to the ZimVie product family. The GenTek restorative portfolio is comprised of Ti-Bases, pre-milled ab
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
Needham initiated coverage of ZimVie with a rating of Hold
Barclays initiated coverage of ZimVie with a rating of Underweight and set a new price target of $9.00
10-Q - ZimVie Inc. (0001876588) (Filer)
8-K - ZimVie Inc. (0001876588) (Filer)
SD - ZimVie Inc. (0001876588) (Filer)
Third Party Net Sales from Continuing Operations of $116.8 millionNet Loss from Continuing Operations of $(9.6) million; Net Loss margin of (8.2%) Adjusted EBITDA[1] from Continuing Operations of $16.1 million; Adjusted EBITDA[1] margin of 13.8%Reduced debt to $235.1 million, ended quarter with cash balance from Continuing Operations of $78.6 million PALM BEACH GARDENS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call today, August 1, 2024, at 4:30 p.m. Eastern Time. "We continued to execute in the
PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufa
Third Party Net Sales from Continuing Operations of $118.2 millionNet Loss from Continuing Operations of ($11.5) million; Net Loss margin of (9.7%) Adjusted EBITDA[1] from Continuing Operations of $12.5 million; Adjusted EBITDA[1] margin of 10.5%Completed sale of spine business for $375 million and repaid $275 million of debt on April 1, 2024 PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call today, May 8, 2024, at 4:30 p.m. Eastern Time. "We have driven great progress in 2024 to
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie's portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date.
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon